Alpha 2.0
Login Register
» Authors » Phillippa Dudley

Phillippa Dudley

Explore the profile of Phillippa Dudley including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 688
Followers 0
Related Specialties
Oncology
Molecular Biology
Radiology
Top 10 Co-Authors
Barry R Davies
Martin Pass
Claire Crafter
Rebecca Ellston
Juliana Maynard
Hannah Greenwood
Sabina C Cosulich
Sally-Ann Ricketts
Sabina Cosulich
John P Vincent
Published In
Mol Cancer Ther
Cancer Res
Mol Imaging Biol
J Med Chem
Cancer Chemother Pharmacol
Affiliations
Soon will be listed here.
Recent Articles
1.
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers
Hudson K, Hancox U, Trigwell C, McEwen R, Polanska U, Nikolaou M, et al.
Mol Cancer Ther . 2016 Feb; 15(5):877-89. PMID: 26839307
The PIK3CA gene, encoding the p110α catalytic unit of PI3Kα, is one of the most frequently mutated oncogenes in human cancer. Hence, PI3Kα is a target subject to intensive efforts...
2.
Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models
Crafter C, Vincent J, Tang E, Dudley P, James N, Klinowska T, et al.
Int J Oncol . 2015 Jun; 47(2):446-54. PMID: 26095475
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signalling network is frequently de-regulated in breast cancer and has been shown to mediate resistance to anti-HER2 agents. Whilst constitutive activation of...
3.
Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363
Yates J, Dudley P, Cheng J, DCruz C, Davies B
Cancer Chemother Pharmacol . 2015 Jun; 76(2):343-56. PMID: 26092323
Purpose: Intermittent dosing of inhibitors of the PI3K/AKT/mTOR network offers the potential to maximize the therapeutic margin. Here, we validate a predictive modeling approach to establish the relative efficacy of...
4.
2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363
Maynard J, Ricketts S, Gendrin C, Dudley P, Davies B
Mol Imaging Biol . 2013 Jan; 15(4):476-85. PMID: 23344784
Purpose: The phosphatidyl inositol 3 kinase, AKT and mammalian target of rapamycin are frequently deregulated in human cancer and are among one of the most promising targets for cancer therapy....
5.
Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background
Davies B, Greenwood H, Dudley P, Crafter C, Yu D, Zhang J, et al.
Mol Cancer Ther . 2012 Feb; 11(4):873-87. PMID: 22294718
AKT is a key node in the most frequently deregulated signaling network in human cancer. AZD5363, a novel pyrrolopyrimidine-derived compound, inhibited all AKT isoforms with a potency of 10 nmol/L...
6.
Diverse heterocyclic scaffolds as allosteric inhibitors of AKT
Kettle J, Brown S, Crafter C, Davies B, Dudley P, Fairley G, et al.
J Med Chem . 2012 Jan; 55(3):1261-73. PMID: 22248236
Wide-ranging exploration of potential replacements for a quinoline-based inhibitor of activation of AKT kinase led to number of alternative, novel scaffolds with potentially improved potency and physicochemical properties. Examples showed...
7.
AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity
Chresta C, Davies B, Hickson I, Harding T, Cosulich S, Critchlow S, et al.
Cancer Res . 2009 Dec; 70(1):288-98. PMID: 20028854
The mammalian target of rapamycin (mTOR) kinase forms two multiprotein complexes, mTORC1 and mTORC2, which regulate cell growth, cell survival, and autophagy. Allosteric inhibitors of mTORC1, such as rapamycin, have...